Recognizing that the complexity of cancer biology makes it virtually impossible for any single therapy to be optimally effective, the overall hypothesis of this research is that, two or more therapies that are mechanistically independent and directed at non-overlapping molecular targets and pathways will provide the most effective treatments. In particular, the dismal statistics for Pancreatic Cancer (PanCa) and its tenacious resistance to current therapies demand innovative approaches with sound mechanistic bases. The goal of this Project is to develop mechanism-based Photodynamic Therapy (PDT) combination regimens to synergistically enhance efficiency of PDT in preclinical models of PanCa where PDT alone has already shown promise. The strategy is to combine PDT with a biologic therapy that is specific to the particular molecular response elicited by PDT in an approach we term Combination Photodynamic Biologic Therapy (CPBT). PDT is an effective treatment for cancer, which kills most cells in solid tumors, and although molecular responses instigated by surviving cells could mitigate overall treatment outcome, these same responses also provide an opportunity in new molecular targets that could greatly enhance specificity and efficiency of treatment outcome. The goals of the study will be realized in 5 specific aims.
Aim 1 will examine molecular responses to sub-lethal PDT and test CPBT targeted to these responses in in vitro organotypic cultures.
Aim 2 -5 will utilize an orthotopic model of PanCa where Aim 2 will optimize PDT parameters in vivo and along with information on the success of CPBT in Aim 1, will guide PDT-based combination treatments in vivo, in Aim 3. Since Gem is standard chemotherapy for PanCa, successful combination treatments in Aim 3 will be further examined in combination with Gem in Aim 4. Finally, the two most successful treatments from Aim 4 will be extended to a long-term survival study in Aim 5. Cores B and C will be used throughout;e.g. on-line measurement of molecular responses, PDT dosimetry, pathology and statistical considerations. The promise of PDT in clinical studies and in several preclinical models for PanCa, our significant preliminary findings and collaborations within the program provide the impetus for the proposed investigations. Potential benefits to public health: the studies in Project 3will lead to newtreatment options for PanCa, a disease with a very poor prognosis with current treatments placing a heavy burden on society in terms of cost and suffering.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA084203-10
Application #
8403910
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
10
Fiscal Year
2013
Total Cost
$185,820
Indirect Cost
$44,671
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Huang, Huang-Chiao; Mallidi, Srivalleesha; Liu, Joyce et al. (2016) Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer Res 76:1066-77
Tangutoori, Shifalika; Spring, Bryan Q; Mai, Zhiming et al. (2016) Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer. Nanomedicine 12:223-34
Obaid, Girgis; Broekgaarden, Mans; Bulin, Anne-Laure et al. (2016) Photonanomedicine: a convergence of photodynamic therapy and nanotechnology. Nanoscale 8:12471-503
Pogue, Brian W; Paulsen, Keith D; Samkoe, Kimberley S et al. (2016) Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention. Med Phys 43:3143
Pogue, Brian W; Elliott, Jonathan T; Kanick, Stephen C et al. (2016) Revisiting photodynamic therapy dosimetry: reductionist & surrogate approaches to facilitate clinical success. Phys Med Biol 61:R57-89
Huggett, Matthew T; Tudzarova, Slavica; Proctor, Ian et al. (2016) Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Oncotarget 7:18495-507
Spring, Bryan Q; Bryan Sears, R; Zheng, Lei Zak et al. (2016) A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. Nat Nanotechnol 11:378-87
de Souza, Ana Luiza Ribeiro; Marra, Kayla; Gunn, Jason et al. (2016) Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer. Br J Cancer 115:805-13
Mohammad, Goran Hamid; Olde Damink, S W M; Malago, Massimo et al. (2016) Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome. PLoS One 11:e0151635
Mallidi, Srivalleesha; Mai, Zhiming; Rizvi, Imran et al. (2015) In vivo evaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints. J Biomed Opt 20:048003

Showing the most recent 10 out of 150 publications